Clinical Trials Directory

Trials / Unknown

UnknownNCT01689805

Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis

Do Mutations in the Filaggrin Gene Have Clinical Importance for the Treatment Outcome in Atopic Dermatitis?

Status
Unknown
Phase
Study type
Observational
Enrollment
800 (estimated)
Sponsor
Helsinki University Central Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Atopic dermatitis is a common disease which affects about one million people in Finland at some stage of their life. In atopic dermatitis we see a superficial inflammation of the skin and a defect in skin barrier function. The filaggrin protein plays a central role in the skin barrier function and studies indicate that about 30% of patients with atopic dermatitis have a mutation in the filaggrin gene. The aim of the study is to investigate whether a mutation in the filaggrin gene affects the clinical treatment outcome in patients with atopic dermatitis. If a mutation predisposes to a worse response to treatment, this could be examined and those patients with the mutation could be given extra treatment support for their atopic dermatitis. The prevalence of filaggrin mutation in the Finnish non-atopic population is studied in the control group.

Conditions

Timeline

Start date
2011-06-01
First posted
2012-09-21
Last updated
2012-09-21

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT01689805. Inclusion in this directory is not an endorsement.